WideCells Group PLC (LON:WDC) is to change its name to Iconic Labs PLC after creating a new media business and bringing onboard former executives from social publishing giant UNILAD.
Tlou Energy Limited (LON:TLOU) updated investors on its drilling programme in Botswana. The company said that two development pods – each containing three wells - have been completed and, they are now de-watering prior to controlled gas flows.
Oriole Resources PLC (LON:ORR) has identified multiple gold-in-soil anomalies at the Wapouzé gold project in Cameroon. Oriole can earn up to a 90% interest in Wapouzé.
Strategic Minerals PLC (LON:SML) (USOTC:SMCDY) is to acquire 100% ownership in the Redmoor tin and tungsten project in Cornwall, after it entered into arrangements with New Age Exploration Limited to acquire its entire 50% shareholding for a maximum consideration of £2.66mln.
ReNeuron Group PLC’s (LON:RENE) Phase I/II clinical trial in the US of its blindness-causing disease, retinitis pigmentosa, has progressed to the next stage. Following a positive data safety monitoring board review of the clinical data from the first Phase II patient cohort in the study, dosing of the second cohort of three Phase II subjects has now commenced, with the first subject in the cohort treated last week at Massachusetts Eye and Ear, in Boston.
ReNeuron also announced that its chief executive officer, Olav Hellebø will present at the Alliance for Regenerative Medicine's Cell & Gene Therapy Investor Day on Thursday, March 21, 2019 at 9:10 am ET (13:10 pm GMT) at The Metropolitan Club in New York City.
NetScientific PLC (LON:NSCI) said on Monday that its portfolio companies Vortex Biosciences and Wanda Inc are set to be wound up. The firm, which invests in development-stage medical and healthcare businesses, had received an indicative proposal from a third party for the sale of its shareholdings in Vortex and Wanda.
WYG PLC (LON:WYG) has announced that its bank has now confirmed its agreement to waive the 31 March 2019 covenant tests and said constructive discussions in relation to the covenant structure attaching to the facilities continue. The group warned on 13 February that it expected it would not meet either of the covenant tests within its bank facility agreements due on 31 March 2019.
Allergy Therapeutics PLC (LON:AGY) received a setback as top-line results from the Phase III clinical trial of its new adjuvanted birch allergoid product disappointed. The profitable drugs development company said the trial did not show a statistically significant difference between those taking the drug and those receiving the placebo.
Primary Health Properties PLC (LON:PHP), which last week completed its merger with MedicX Fund Limited, has contracted to acquire, by way of forward funding, a new primary healthcare medical centre in Kew, London. The FTSE 250-listed firm said the property is due to be completed in October 2019 and will have a net internal area of approximately 845 square metres for a total cost of £4.6mln.
Arix Bioscience PLC (LON:ARIX) said it has invested US$15mln (£11.3mln) in Imara, a company developing treatments for sickle cell disease.
Eco Atlantic Oil & Gas Ltd (LON:ECO) (CVE:EOG) has revealed the impressive findings of a new resource assessment for the Orinduik Block, offshore Guyana, ahead of exploration drilling later this year. Consultant Gustavson Associates has estimated some 3.98bn barrels of prospective resources across fifteen exploration areas, which for Eco’s 15% stake in Orinduik equates to 597.3mln barrels net to the AIM-quoted firm.
Chaarat Gold Holdings Limited (LON:CGH) is to receive a cash boost of US$31.5mln to develop the Tulkubash and Kyzyltash projects in the Kyrgyz Republic. Turkish mining specialist Ciftay will pay the cash in increments and become the mining and construction contractor at Tulkubash with a 12.5% stake in both that project and Kyzyltash.
Kavango Resources PLC (LON:KAV)has completed the second phase of its airborne electromagnetic survey over the northern section of the Kalahari Suture Zone. The survey covered approximately 2,100 line-kilometres to the north of Hukuntsi in southwest Botswana.
Bluebird Merchant Ventures Ltd (LON:BMV) has raised £436,500 to fund the next stage of its mine re-opening project in South Korea. A placing of 19.4mln shares at 2.25p was heavily backed by management, with the senior executives putting up £186,500 of the amount raised.
Motif Bio PLC (LON:MTFB) (NASDAQ:MTFB) has appointed long-standing board member Bruce Williams as its interim chairman to replace Richard C.E. Morgan who is stepping down with immediate effect to focus on other business commitments.
W Resources PLC (LON:WRES) is continuing with construction and installation work at the La Parilla project in Spain as part of its ramp up to full production. First tin and tungsten was produced from the project late last year.
Salt Lake Potash Ltd (ASX:SO4) (LON:SO4) has revealed a significant extension to the resource at Lake Way in Western Australia following completion of an exploration program across the whole of the lake. The estimated total resource at Lake Way has increased to 73 million tonnes (Mt) of SOP (sulphate of potash) calculated using total porosity and 8.2Mt of SOP calculated using drainable porosity.
US Oil & Gas PLC (LON:USOP) told investors that dialogue is continuing with regulatory agencies regarding its permit application for the hydraulic fracturing of the Eblana-3 well, in Nevada. The explorer added that it has undertaken a comprehensive study of local water resources, requiring multiple samples be collected over an extended period and be independently analysed.
The Marketing Group PLC (NASDAQ OMX:TMG), which trades as RYVL, said its shares were suspended from trade on Nasdaq First North on March 14, 2019 due to non-disclosure of inside information to the market after ‘human error’ led to a tweet from its CEO saying “Q1 results will be amazing.” The company confirmed that revenues for Q1 2019 are forecast to be between €1.9mln-€2.1mln, with operating EBITDA of between €0.7mln-€0.9mln, an increase compared to 2018. It also noted that Nasdaq has resolved that due to a change in its operations, the group is therefore no longer compliant with listing requirements and needs to file a new application for admission to trading on Nasdaq First North on April 1, 2019 at the latest or otherwise Nasdaq may resolve to de-list the shares.
IXICO PLC (LON:IXI), the digital technologies company serving neuroscience, has said it received notification on 18 March 2019 that its non-executive chairman, Charles Spicer, acquired 70,175 ordinary shares in the company at a price of 28.5p each, to be held in his SIPP account. Following this purchase, the group added, Spicer is interested in 192,775 ordinary shares in the company, representing 0.41% of the current issued share capital.
Summit Therapeutics PLC (LON:SUMM) (NASDAQ:SMMT), a leader in new mechanism antibiotic innovation, has announced that its management will present at two upcoming conferences: Superbugs & Superdrugs 2019: The Development of Precision Antibiotics: Agents Designed to Meet the Demands of Stewardship, on 18 March 2019 at 1:40pm GMT in London; and Oppenheimer 29th Annual Healthcare Conference: corporate presentation on 20 March 2019 at 2:10pm EDT in New York City.